Longer Patents for Increased Generic Competition in the US

  title={Longer Patents for Increased Generic Competition in the US},
  author={Henry G. Grabowski and John M. Vernon},
The 1984 Waxman-Hatch Act had two main objectives. Title I was designed to promote price competition by establishing an abbreviated new drug application (ANDA) process for generic market entry. Title II was designed to encourage drug innovation by restoring some of the patent life lost during the lengthy FDA regulatory process. In this paper, we consider whether these twin objectives have been realised during the first decade of the Act’s existence. First, we investigate the pattern of generic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 53 extracted citations


Publications referenced by this paper.
Showing 1-10 of 17 references

Prospects for returns to pharmaceutical R & D under health care reform forthcoming

  • H Grabowski, J Vernon
  • Competitive strategies in the pharmaceutical…
  • 1996

Prospects for returns to pharmaceutical R&D under health care reform forthcoming. In: Helms RB, editor. Competitive strategies in the pharmaceutical industry

  • H Grabowski, J. Vernon
  • 1996

vs Bruce Lehman, vs District Court for the Eastern District of Virginia, Civil action

  • Hoffmann La Roche Inc
  • 1995

Obtaining an SPC in Europe

  • B Hansen, C. Hill
  • Patents and Licensing
  • 1994

Catalysts for change: the impact of generic drugs on the pharmaceutical industry

  • HK Shaw
  • Spectrum, Report 38,
  • 1992

Implementation of the Orphan Act: 1983-1991

  • S Shulman, B Bienz-Tadmor, PS Seo
  • Food and Law J
  • 1992

Patent expiration, entry, and competition in the US pharmaceutical industry: an exploratory analysis

  • RE Caves, MD Whinston, MA. Hurwitz
  • Brookings Papers on Economic Activity…
  • 1991

Similar Papers

Loading similar papers…